Camptosar

(Irinotecan)

ApprovedSmall molecule

Irinotecan is a chemotherapy drug used to treat certain types of cancer, including colorectal cancer and small cell lung cancer, by damaging cancer cell DNA to stop them from growing.[2] Camptosar is currently approved and in use across 100 indications[4].[1]

Camptosar is one of 1125 small molecule programs targeting Pancreatic Adenocarcinoma. It is currently in Approved.

100

Indications

642

Total Trials

Active Trials

1,124

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Pancreatic AdenocarcinomaCompleted

Pancreatic CancerActive, not recruiting

Small Cell Lung CancerCompleted

LymphomaActive, not recruiting

Ewing SarcomaWithdrawn

Advanced Malignant TumorsNot yet recruiting

Second-Line TreatmentRecruiting

Patients With Advanced Solid TumorsTerminated

Efficacy and SafetyCompleted

Refractory Solid TumorsActive, not recruiting

Pancreatic AdenocarcinomaPhase 2

Completed

Pancreatic CancerPhase 3

Active, not recruiting

Small Cell Lung CancerPhase 3

Completed

LymphomaPhase 1

Active, not recruiting

Ewing SarcomaPhase 2

Withdrawn

Advanced Malignant TumorsPhase 2

Not yet recruiting

Second-Line TreatmentPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Terminated

Efficacy and SafetyPhase 2

Completed

Refractory Solid TumorsPhase 2

Active, not recruiting

Showing 10 of 100 indications

Competition

Competitive Landscape

401 competitors in Lymphoma

#DrugCompanyPhaseTrials

Camptosar

Pfizer

Approved

2 2

Zofran

Novartis

Preclinical

2 3

Cabenuva

GSK

Preclinical

1 4

Norvir

AbbVie

Preclinical

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Kenalog

BBausch Health Americas, Inc.

Preclinical

1 7

Nuvigil

NNuvo Research GmbH

Preclinical

1 8

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 9

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

—10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Not yet recruiting

Patients With Locally Advanced Rectal Cancer

NCT04443543

Q2 2027

N/ARecruiting

Clinical Trial

NCT05391126

Phase 1Recruiting

Oxaliplatin

NCT04361708

Q4 2027

Phase 3Active, not recruiting

Metastatic Colorectal Cancer

NCT04607421

Q1 2028

Phase 1Recruiting

Combination Therapy

NCT05694715

Clinical

Trials by Indication[1]

Metastatic Colorectal Cancer34 trials

Vitamin D3 With Chemotherapy and Bevacizumab in Treating Patients With Advanced or Metastatic Colorectal Cancer

Active, not recruiting·AAlliance for Clinical Trials in Oncology·Phase 3·NCT04094688·455 enrolled

A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer

Completed·CChinese Academy of Medical Sciences·Phase 2·NCT04247984·264 enrolled

ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer

Completed· Daiichi Sankyo logo

Daiichi Sankyo·Phase 1/2·NCT01075048·131 enrolled

Show 31 more trials

First-line FOLFOXIRI In Combination With Bevacizumab For Metastatic Colorectal Cancer

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT01163396·57 enrolled

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT04607421·831 enrolled

A Study of AK112 With or Without AK117 in Metastatic Colorectal Cancer

Active, not recruiting·AAkeso·Phase 2·NCT05382442·254 enrolled

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Unknown status·SShanghai JMT-Bio Inc.·Phase 2·NCT06089330·102 enrolled

Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer

Completed·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT02138617·100 enrolled

The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07134205·252 enrolled

Second-line Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Fruquintinib Versus Doublet Chemotherapy (FOLFOX or FOLFIRI) Plus Bevacizumab in Metastatic Colorectal Cancer

Not yet recruiting·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT07150403·74 enrolled

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT04513951·62 enrolled

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.

Withdrawn· Roche logo

Roche·Phase 2·NCT00577109

A Phase III Clinical Study of Napabucasin (GB201) Plus FOLFIRI in Adult Patients With Metastatic Colorectal Cancer

Unknown status·11Globe Health Institute·Phase 3·NCT03522649·668 enrolled

Individualization of Dosage of Irinotecan in the FOLFIRI According to the Genetic Polymorphism of UGT1A1 in the First Line Treatment of Metastatic Colorectal Cancer

Completed·CCentre Jean Perrin·Phase 2·NCT01963182·47 enrolled

Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated Levels of Plasma FGF

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01367275·8 enrolled

A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 3·NCT02753127·1,253 enrolled

OPAL Study: A Study of Avastin (Bevacizumab) in Combination With FOLFOXIRI in Patients With Previously Untreated Metastatic Colorectal Cancer

Completed· Roche logo

Roche·Phase 2·NCT00940303·97 enrolled

Temsirolimus and Irinotecan for Treatment Resistant Patients With Metastatic Colorectal Cancer and KRAS Mutations

Completed·VVejle Hospital·Phase 2·NCT00827684·50 enrolled

Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT03374254·116 enrolled

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

Completed·—·Phase 2·NCT02292758·36 enrolled

Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)

Terminated· Gilead logo

Gilead·Phase 2·NCT05330429·77 enrolled

Trial Comparing Two Strategies of Chemotherapy for Metastatic Colorectal Cancer

Completed·GGustave Roussy, Cancer Campus, Grand Paris·Phase 3·NCT00126256·570 enrolled

Evaluating Panitumumab (ABX-EGF) in Patients With Metastatic Colorectal Cancer

Completed· Amgen logo

Amgen·Phase 2·NCT00111761·43 enrolled

For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy

Terminated· Pfizer logo

Pfizer·Phase 2·NCT00037180·212 enrolled

Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab

Completed·UUNICANCER·Phase 2·NCT01442649·133 enrolled

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

Withdrawn· AstraZeneca logo

AstraZeneca·Phase 2·NCT00233623·190 enrolled

SALIRI Based Regimen as First-line Treatment for Advanced Metastatic Colorectal Cancer

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT05160896·90 enrolled

AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer

Recruiting·AAkeso·Phase 3·NCT06951503·560 enrolled

Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

Completed· Amgen logo

Amgen·Phase 2·NCT00332163·95 enrolled

A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.

Completed· Roche logo

Roche·Phase 3·NCT00642577·214 enrolled

FOLFOXIRI + Bev + Atezo vs FOLFOXIRI + Bev as First-line Treatment of Unresectable Metastatic Colorectal Cancer Patients

Completed·GGruppo Oncologico del Nord-Ovest·Phase 2·NCT03721653·218 enrolled

A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer

Completed·EEpicentRx, Inc.·Phase 2·NCT02096354·62 enrolled

A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00778102·80 enrolled

Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 +/- Irinotecan and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver

Recruiting·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT02885753·348 enrolled

Colorectal Cancer17 trials

Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study

Recruiting·SSun Yat-sen University·Phase 2·NCT06547203·34 enrolled

Metformin Plus Irinotecan for Refractory Colorectal Cancer

Unknown status·—·Phase 2·NCT01930864·41 enrolled

Irinotecan Discontinuation and Reintroduction for Advanced Colorectal Cancer

Terminated·GGachon University Gil Medical Center·Phase 2·NCT00320320·72 enrolled

Show 14 more trials

A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer

Active, not recruiting·AAkeso·Phase 1/2·NCT05846867·170 enrolled

Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer

Completed·IIsofol Medical AB·Phase 1/2·NCT02244632·105 enrolled

Comparison of Interleukin-11 and rhTPO for Recurrent Colorectal Cancer Patients With Thrombocytopenia

Unknown status·FFudan University·Phase 2·NCT03823079·50 enrolled

High-dose FOLFIRI in Advanced Colorectal Cancer Patients With Wild-type UGT1A1*6 and *28

Unknown status·SShanghai Changzheng Hospital·Phase 2·NCT03329183·90 enrolled

Study of Capecitabine With Irinotecan and Oxaliplatin (Eloxatin) in Advanced Colorectal Cancer

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00215982·24 enrolled

FOLFOXIRI for Neoadjuvant Treatment of High-risk Locally Advanced Colorectal Cancer

Unknown status·WWest China Hospital·Phase 2·NCT05018182·69 enrolled

Evaluation of Low-dose Irinotecan and Cyberknife® SBRT to Treat Colorectal Cancer With Limited Liver Metastasis

Withdrawn·WWake Forest University Health Sciences·N/A·NCT01847495

Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal Cancer

Completed·HHellenic Cooperative Oncology Group·Phase 2·NCT02129257·73 enrolled

FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT01226719·15 enrolled

FOLFIRI or mFOLFOX6 in Adjuvant Chemotherapy in Advanced Colorectal Cancer

Unknown status·SSun Yat-sen University·Phase 3·NCT01566942·200 enrolled

Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT00766220

Phase II Study of 2-weekly RAILIRI Versus FOLFIRI as Second-line Treatment in Advanced Colorectal Cancer Patients

Unknown status·FFudan University·Phase 2·NCT02376452·100 enrolled

Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors

Terminated·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT01858662·4 enrolled

Irinotecan/Oxaliplatin/5-Fluorouracil/Leucovorin/Cetuximab As First Line Treatment In Colorectal Cancer

Completed·—·Phase 2·NCT00689624·30 enrolled

Pancreatic Cancer10 trials

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1·NCT02231723·139 enrolled

Nivolumab in Combination With Chemotherapy Pre-Surgery in Treating Patients With Borderline Resectable Pancreatic Cancer

Completed·JJonsson Comprehensive Cancer Center·Phase 1·NCT03970252·28 enrolled

A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1/2·NCT03535727·48 enrolled

Show 7 more trials

The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer

Unknown status·FFudan University·Phase 2·NCT03403101·65 enrolled

Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer

Active, not recruiting·SSeoul National University Hospital·Phase 2·NCT04447092·77 enrolled

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276744·249 enrolled

A Study of Administering FOLFIRINOX Before Surgery For Potentially Curable Pancreatic Cancer

Unknown status·PPetr Kavan·Phase 2·NCT03167112·20 enrolled

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Completed·—·Phase 1/2·NCT03699319·49 enrolled

Efficacy and Tolerance Evaluation in FOLFIRINOX Dose Adjusted in Elderly Patients With a Metastatic Pancreatic Cancer

Completed·IInstitut Cancerologie de l'Ouest·Phase 2·NCT02143219·72 enrolled

NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT06941857·20 enrolled

Gastric Cancer7 trials

Pre-operation Chemo and Antibody Therapy Followed by Surgical Resection and Adjuvant Chemoradiation for Gastric Cancer

Completed·NNYU Langone Health·Phase 2·NCT00857246·30 enrolled

Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer

Completed·—·Phase 2·NCT00394433·38 enrolled

ILF With/Without Cisplatin for Advanced Gastric Cancer

Unknown status·GGachon University Gil Medical Center·Phase 2·NCT00320294·86 enrolled

Show 4 more trials

Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT05669807·184 enrolled

Phase II Trial of AUY922 vs. Comparators in Advanced Gastric Cancer

Completed· Novartis logo

Novartis·Phase 2·NCT01084330·68 enrolled

Pegliposomal Doxorubicin and 5-fluorouracil as Second Line Therapy for Metastatic Gastric Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT04358341·136 enrolled

Triplet Combination of Cytotoxics as First-line Treatment for Metastatic Gastric Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT04358354·388 enrolled

Small Cell Lung Cancer7 trials

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00248482·6 enrolled

Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients

Completed·CCancer Research and Biostatistics Clinical Trials Consortium·Phase 1/2·NCT01941316·78 enrolled

Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00695292·37 enrolled

Show 4 more trials

Chemotherapy in Patients With Relapsed Small Cell Lung Cancer in Combination With Allopurinol and MycoPhenolate (CLAMP Trial)

Terminated·WWashington University School of Medicine·Phase 1·NCT05049863·17 enrolled

Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193375·60 enrolled

Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)

Completed·NNational Cancer Center, Korea·Phase 2·NCT00452634·62 enrolled

Study of Relationship Between UGT1A1 Gene Polymorphism and Toxicity and Efficacy of Irinotecan in Small Cell Lung Cancer

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT01635400·50 enrolled

73 more indications

Chemotherapy5 trials

A Study of Systemic Chemotherapy With CPT-11 Plus HAI (FUDR+L-OHP) in Patients With Initially Unresectable CRCLM

Completed·SSun Yat-sen University·Phase 2·NCT03493061·60 enrolled

SI-B001 as a Single Agent or in Combination With Chemotherapy in the Treatment of Digestive System Malignancies

Terminated·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05039944·7 enrolled

Multi-agent Low Dose Chemotherapy GAX-CI Followed by Olaparib and Pembro in Metastatic Pancreatic Ductal Cancer.

Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT04753879·38 enrolled

Show 2 more trials

A Pilot, Prospective, Non-randomized Evaluation of the Safety of Anakinra Plus Standard Chemotherapy

Completed·—·Phase 1·NCT02021422·13 enrolled

FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM

Terminated·SSun Yat-sen University·Phase 3·NCT03678428·92 enrolled

Treatment5 trials

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

Terminated·TTufts Medical Center·Phase 3·NCT01014767·27 enrolled

SMMART Adaptive Clinical Treatment (ACT) Trial

Withdrawn·OOHSU Knight Cancer Institute·Phase 1·NCT05238831

Show 2 more trials

Combination of CPT-11 and LoHP vs Combination of 5-FU, Leucovorin and LoHP as 1st Line Treatment in Gastric Patients

Completed·HHellenic Oncology Research Group·Phase 2·NCT00447967·110 enrolled

Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC

Active, not recruiting·UUniversity of Wisconsin, Madison·Phase 2·NCT04587128·34 enrolled

Esophageal Cancer5 trials

Weekly Cisplatin/Irinotecan and Radiotherapy in Patients With Locally Advanced Esophageal Cancer: Phase II Trial

Completed·UUniversity Hospital, Rouen·Phase 2·NCT00213486·43 enrolled

Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT01928290·67 enrolled

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Completed·—·Phase 2·NCT00165490·19 enrolled

Show 2 more trials

Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer

Completed·JJiangsu HengRui Medicine Co., Ltd.·Phase 3·NCT03099382·457 enrolled

Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer

Completed·—·Phase 2·NCT00137852·35 enrolled

Glioblastoma Multiforme4 trials

A Study to Evaluate Bevacizumab Alone or in Combination With Irinotecan for Treatment of Glioblastoma Multiforme (BRAIN)

Completed· Roche logo

Roche·Phase 2·NCT00345163·167 enrolled

A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

Unknown status·LLeaf Vertical Inc.·Phase 1/2·NCT03607643·160 enrolled

Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme

Completed·KKaty Peters·Phase 2·NCT00979017·41 enrolled

Show 1 more trial

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Terminated·MM.D. Anderson Cancer Center·Phase 1·NCT00671801·24 enrolled

Advanced Cancer4 trials

OSI-906 and Irinotecan in Patients With Advanced Cancer

Terminated·UUniversity of Colorado, Denver·Phase 1·NCT01016860·16 enrolled

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Terminated· Pfizer logo

Pfizer·Phase 1·NCT01347866·105 enrolled

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Terminated·EEpicentRx, Inc.·Phase 1·NCT02801097·28 enrolled

Show 1 more trial

A Dose Escalation Study of MM-398 Plus Irinotecan in Patients With Unresectable Advanced Cancer

Completed·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 1·NCT02640365·10 enrolled

Adenocarcinoma4 trials

Preoperative Folfirinox, Radiation Therapy for Resectable Adenocarcinoma of the Pancreas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01560949·34 enrolled

FOLFOX6 Versus mFOLFIRINOX as First Line Chemotherapy in Metastatic Gastric Cancer or Esophagogastric Junction Adenocarcinoma (Type II-III)

Unknown status·—·Phase 2·NCT04442984·326 enrolled

JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma.

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT07284134·560 enrolled

Show 1 more trial

FOLFIRI or FOLFOX With or Without Cetuximab in Patients With Metastatic Adenocarcinoma of the Colon or Rectum

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00077233·238 enrolled

Malignant Glioma3 trials

High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma

Completed·KKentuckiana Cancer Institute·Phase 1/2·NCT00283556·30 enrolled

Panitumumab and Irinotecan for Malignant Gliomas

Terminated·AAnnick Desjardins·Phase 2·NCT01017653·16 enrolled

Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma

Completed·—·Phase 2·NCT00352521·20 enrolled

Breast Cancer3 trials

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT02030678·124 enrolled

Irinotecan for Advanced and Metastatic Breast Cancer

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT03562390·124 enrolled

Irinotecan in Patients With Advanced Metastatic Breast Cancer Who Have Experienced Failure of an Anthracycline, a Taxane, and Capecitabine

Completed· Pfizer logo

Pfizer·Phase 2·NCT00072852·134 enrolled

Advanced Solid Tumors3 trials

A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1/2·NCT03184870·332 enrolled

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Completed· Gilead logo

Gilead·Phase 1·NCT01803282·236 enrolled

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00954512·15 enrolled

Patients With Advanced Solid Tumors3 trials

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors

Terminated· Roche logo

Roche·Phase 1·NCT00811993·104 enrolled

Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors

Completed·UUniversity of Chicago·Phase 1·NCT00708773·68 enrolled

Refractory Solid Tumors3 trials

Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors

Active, not recruiting· Pfizer logo

Pfizer·Phase 2·NCT03709680·128 enrolled

A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00057473

A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

Completed·UUniversity of Colorado, Denver·Phase 1·NCT02596503·2 enrolled

Esophageal Squamous Cell Carcinoma3 trials

Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma

Terminated· BeiGene logo

BeiGene·Phase 2·NCT05461794·96 enrolled

Apatinib and Irinotecan Combination Treatment in Unresectable or Metastatic Esophageal Squamous Cell Carcinoma

Terminated·PPeking University·Phase 2·NCT03251417·11 enrolled

SI-B001 Combined With Irinotecan in the Treatment of Recurrent Metastatic Esophageal Squamous Cell Carcinoma.

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 2·NCT05022654·22 enrolled

Neuroblastoma3 trials

Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children

Active, not recruiting·UUniversity of Birmingham·Phase 2·NCT02308527·225 enrolled

Neuroblastoma Protocol 2008: Therapy for Children With Advanced Stage High Risk Neuroblastoma

Terminated·SSt. Jude Children's Research Hospital·Phase 2·NCT00808899·4 enrolled

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Completed· Eli Lilly logo

Eli Lilly·Phase 1/2·NCT04238819·47 enrolled

Ewing's Sarcoma2 trials

CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Active, not recruiting· Eli Lilly logo

Eli Lilly·Phase 2·NCT05440786·46 enrolled

A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma

Completed·GGradalis, Inc.·Phase 2·NCT02511132·22 enrolled

Pancreatic Ductal Adenocarcinoma2 trials

Study Investigating the Association of NP137 With mFOLFIRINOX in Locally Advanced Pancreatic Ductal Adenocarcinoma

Completed·UUniversity Hospital, Grenoble·Phase 1·NCT05546853·43 enrolled

Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma

Recruiting·UUniversity of Miami·Phase 2·NCT07096362·50 enrolled

Phase II2 trials

Nordic 8 - A Phase II Trial

Completed·PPer Pfeiffer·Phase 2·NCT01867697·173 enrolled

Phase II Study of Irinotecan and Panitumumab

Completed·WWeijing Sun, MD, FACP·Phase 2·NCT00836277·24 enrolled

Oxaliplatin2 trials

Perioperative FOLFIRI VS Adjuvant FOLFIRI in Resectable Advanced CRC Failed to Oxaliplatin

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT02087475·360 enrolled

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

Recruiting·UUniversity of Chicago·Phase 1·NCT04361708·54 enrolled

Second-line Treatment2 trials

Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·Phase 2·NCT03030937·74 enrolled

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Recruiting·FFudan University·Phase 2·NCT05229003·44 enrolled

Trial2 trials

The Sagittarius Trial

Recruiting·IIFOM ETS - The AIRC Institute of Molecular Oncology·Phase 3·NCT06490536·700 enrolled

Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan

Completed·UUniversity of Southern California·Phase 1·NCT00183859·42 enrolled

Solid Tumors2 trials

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors

Completed·PPharmaMar·Phase 1/2·NCT02611024·316 enrolled

A Study of TXN10128 in Subjects With Solid Tumors

Recruiting·TTxinno Bioscience Inc.·Phase 1·NCT05978492·96 enrolled

Intestinal Cancer2 trials

A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer

Completed· Sumitomo Pharma America, Inc. logo

Sumitomo Pharma America, Inc.·Phase 1/2·NCT02024607·495 enrolled

Study of Irinotecan Administered as a Continuous Infusion and Radiation Therapy for Upper Gastrointestinal Cancers

Completed·UUniversity of Southern California·Phase 1·NCT00183846·22 enrolled

Clinical Trial2 trials

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care

Recruiting·—·N/A·NCT05391126·178 enrolled

Treatment Extension Study for Patients Who Have Previously Participated and Have Benefited From Iniparib in a Clinical Trial

Completed· Sanofi logo

Sanofi·Phase 3·NCT01593228·37 enrolled

Lymphoma2 trials

Phase I Dose Escalation and Pharmacokinetics Clinical Trial of Mitoxantrone Hydrochloride Liposome in Children With Relapsed and Refractory Lymphoma and Solid Tumors

Active, not recruiting·SSun Yat-sen University·Phase 1·NCT05620862·68 enrolled

Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Completed·CChildren's Oncology Group·Phase 1·NCT03323034·30 enrolled

Biliary Tract Cancer2 trials

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Completed·MMayo Clinic·Phase 2·NCT04072445·28 enrolled

GAMBIT Trial: Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer

Unknown status·—·Phase 2·NCT01859728·48 enrolled

Pediatric Patients2 trials

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Terminated·AActuate Therapeutics Inc.·Phase 1·NCT04239092·40 enrolled

Evaluation of FDOPA-PET/MRI in Pediatric Patients With CNS Tumors

Completed·WWashington University School of Medicine·Phase 1·NCT01999270·6 enrolled

Fluorouracil2 trials

Phase I Irinotecan, 5-Fluorouracil and Leucovorin Combination

Completed· Sanofi logo

Sanofi·Phase 1·NCT00507091·24 enrolled

Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01046864·49 enrolled

Patients With Solid Tumors2 trials

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Completed·HHMeany·Phase 1·NCT01518413·17 enrolled

Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors

Unknown status·BBiotech Pharmaceutical Co., Ltd.·Phase 1·NCT02395068·40 enrolled

Metastatic2 trials

Second-line FOLFIRI + Panitumumab in Subjects With Wild Type RAS Metastatic Colorectal

Unknown status·GGrupo Espanol Multidisciplinario del Cancer Digestivo·Phase 2·NCT03751176·31 enrolled

Irinotecan/Cetuximab Followed by XELOX/Cetuximab vs the Reverse Sequence in Metastatic CRC

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00755534·68 enrolled

Advanced Cancers2 trials

9-ING-41 in Patients with Advanced Cancers

Active, not recruiting·AActuate Therapeutics Inc.·Phase 2·NCT03678883·350 enrolled

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Completed·MMerrimack Pharmaceuticals·Phase 1·NCT01451632·48 enrolled

Ovarian Cancer1 trial

Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Completed·NNYU Langone Health·Phase 2·NCT01091259·29 enrolled

Rhabdomyosarcoma1 trial

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting·SSt. Jude Children's Research Hospital·Phase 2·NCT01871766·115 enrolled

Advanced Sarcoma1 trial

Irinotecan (Camptosar) in Patients With Advanced Sarcomas

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00509860·38 enrolled

Rectum Cancer1 trial

A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Terminated· Eli Lilly logo

Eli Lilly·Phase 2·NCT00845039·4 enrolled

Tislelizumab1 trial

Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab

Recruiting·FFujian Cancer Hospital·Phase 1/2·NCT05319639·51 enrolled

Unresectable Cancer1 trial

Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer

Terminated·IImmodulon Therapeutics Ltd·Phase 1/2·NCT03009058·2 enrolled

Advanced Solid Malignancies1 trial

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Completed· Sanofi logo

Sanofi·Phase 1·NCT01930552·20 enrolled

Resistance1 trial

Study to Evaluate Mechanisms of Acquired Resistance to Panitumumab

Completed·NNantBioScience, Inc.·Phase 2·NCT00891930·74 enrolled

Gastric Adenocarcinoma1 trial

Study of Nimotuzumab and Irinotecan as Second Line With Recurrent or Metastatic Gastric Adenocarcinoma

Unknown status·PPeking University·Phase 2·NCT03400592·55 enrolled

Metastases1 trial

Chemotherapies Associated With Targeted Therapies on the Resection Rate of Hepatic Metastases

Completed·UUNICANCER·Phase 2·NCT01442935·256 enrolled

Solid Tumor Malignancies1 trial

Capecitabine or 5-Fluorouracil in Combination With Irinotecan and Cisplatin in Patients With Solid Tumor Malignancies

Completed·—·Phase 1·NCT00215501·54 enrolled

Randomized1 trial

Randomized Phase III Study of Folfiri+Avastin Versus Xeliri+Avastin as 1st Line Treatment of CRC

Completed·HHellenic Oncology Research Group·Phase 3·NCT00469443·330 enrolled

Single Ascending Dose1 trial

Phase I Single Ascending Dose/Multiple Ascending Dose in Patients Treated With AZD7762 and Irinotecan

Terminated· AstraZeneca logo

AstraZeneca·Phase 1·NCT00473616·60 enrolled

CRC1 trial

Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT03493048·146 enrolled

Temozolomide1 trial

Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy

Completed·UUniversity of Oklahoma·Phase 1·NCT00222443·40 enrolled

Acute Leukemia1 trial

Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents

Unknown status·SSeoul National University Hospital·Phase 1·NCT01239485·18 enrolled

Liver Cancer1 trial

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

Terminated·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT01336985·5 enrolled

Genetic Polymorphism1 trial

Study of Genetic Polymorphisms of Drug Transporters and Orphan Nuclear Receptors on Treatment Effects of Irinotecan

Unknown status·NNational Cancer Center, Korea·N/A·NCT00507143·100 enrolled

Intraperitoneal Chemotherapy1 trial

Efficacy of Hyperthermic Intraperitoneal Chemotherapy

Recruiting·UUppsala University·Phase 3·NCT04861558·213 enrolled

Pancreatic Carcinoma1 trial

A Randomized Phase III Trial Comparing Folfirinox to Gemcitabine in Locally Advanced Pancreatic Carcinoma

Completed·UUNICANCER·Phase 3·NCT02539537·171 enrolled

Molecular Targeted Therapy1 trial

Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma

Completed·UUniversity of Regensburg·Phase 2·NCT02596828·4 enrolled

Borderline Resectable1 trial

The Efficacy of Bevacizumab Combined With m-FOLFOXIRI in Borderline Resectable Colorectal Liver Metastases

Unknown status·NNational Cheng-Kung University Hospital·Phase 2·NCT03711240·40 enrolled

Patients With Locally Advanced Rectal Cancer1 trial

An Adaptive-design Prospective Cohort Study of Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer

Not yet recruiting·FFudan University·Phase 2·NCT04443543·222 enrolled

Metastatic Solid Tumors1 trial

Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01653470·141 enrolled

Microsatellite Stable1 trial

Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer

Unknown status·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 2·NCT03608046·59 enrolled

Targeted Therapy1 trial

Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy

Completed·TThe Christie NHS Foundation Trust·Phase 2·NCT01225744·47 enrolled

Adjuvant Chemotherapy1 trial

Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00068692·225 enrolled

Lung Cancer1 trial

Irinotecan Plus Cisplatin Compared With Etoposide Plus Cisplatin for Extensive Stage Small-cell Lung Cancer

Unknown status·GGuangdong Association of Clinical Trials·Phase 4·NCT02348450·308 enrolled

Intraperitoneal1 trial

Intraperitoneal and System Chemotherapy Versus XELOX as First-line Chemotherapy for mCRC

Unknown status·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Phase 2·NCT03792269·100 enrolled

Esophageal Adenocarcinoma1 trial

TAS-102 and Irinotecan in 2L+ Gastric and Gastroesophageal Adenocarcinoma

Completed·UUniversity of California, Irvine·Phase 1·NCT04074343·20 enrolled

Combination Therapy1 trial

Combination Therapy in Cancers With Mutations in DNA Repair Genes

Recruiting·UUniversity of California, San Francisco·Phase 1·NCT05694715·24 enrolled

Gastroesophageal Junction Cancer1 trial

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 2·NCT02485834·5 enrolled

Recurrent or Metastatic1 trial

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

Terminated·UUniversity of California, Irvine·Phase 2·NCT00256269·4 enrolled

First-line Treatment1 trial

mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA

Unknown status·FFujian Cancer Hospital·N/A·NCT03045770·150 enrolled

RAS Mutation1 trial

Irinotecan and Panitumumab as 3rd Line Treatment for mCRC Without KRAS Mutations

Completed·VVejle Hospital·Phase 2·NCT00792363·32 enrolled

TED1 trial

Study of Selumetinib (AZD6244)(ARRY-142886) in Combination With Irinotecan in Previously Treated Patients With Colorec

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT01116271·32 enrolled

Neuroendocrine Carcinoma1 trial

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

Completed·UUniversity of California, San Francisco·Phase 2·NCT03136055·36 enrolled

Pancreatic Adenocarcinoma1 trial

Xeloxiri as First-line Treatment in Patients With Advanced Unresectable Pancreatic Adenocarcinoma

Completed·TThe University of Hong Kong·Phase 2·NCT01558869·37 enrolled

Efficacy and Safety1 trial

To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCC

Unknown status·PPeking University·Phase 2·NCT05818982·72 enrolled

Metastatic Cancer1 trial

A Study of Avastin (Bevacizumab) in Combination Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Completed· Roche logo

Roche·Phase 2·NCT01131078·306 enrolled

Cisplatin1 trial

Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLC

Terminated·LLeo W. Jenkins Cancer Center·Phase 2·NCT02275806·4 enrolled

Carcinoma1 trial

A Protocol of Irinotecan for Carcinoma of the Lung

Withdrawn·SSusanne Arnold·Phase 2·NCT01654081

First Line Therapy1 trial

Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT02564263·628 enrolled

Unspecified2 trials

Resection Observatory

Completed· Sanofi logo

Sanofi··NCT05178745·140 enrolled

Second-Line Irinotecan vs. ILF for AGC

Unknown status·GGachon University Gil Medical Center·Phase 2·NCT00509964·50 enrolled

Regulatory

FDA Approval Timeline[5]

Jun 14, 1996

CAMPTOSAR

NDA NDA020571

Jun 14, 1996

CAMPTOSAR

NDA NDA020571

Mar 7, 1997

CAMPTOSAR

NDA NDA020571

Jun 5, 1997

CAMPTOSAR

NDA NDA020571

Oct 21, 1997

CAMPTOSAR

NDA NDA020571

Dec 10, 1997

CAMPTOSAR

NDA NDA020571

Jan 15, 1998

CAMPTOSAR

NDA NDA020571

Mar 18, 1998

CAMPTOSAR

NDA NDA020571

Oct 22, 1998

CAMPTOSAR

NDA NDA020571

Apr 20, 2000

CAMPTOSAR

NDA NDA020571

Jul 29, 2000

CAMPTOSAR

NDA NDA020571

Aug 6, 2001

CAMPTOSAR

NDA NDA020571

Nov 5, 2001

CAMPTOSAR

NDA NDA020571

May 16, 2002

CAMPTOSAR

NDA NDA020571

Jul 30, 2002

CAMPTOSAR

NDA NDA020571

Jun 24, 2004

CAMPTOSAR

NDA NDA020571

Dec 3, 2004

CAMPTOSAR

NDA NDA020571

Jun 7, 2005

CAMPTOSAR

NDA NDA020571

Jul 21, 2005

CAMPTOSAR

NDA NDA020571

Jul 21, 2005

CAMPTOSAR

NDA NDA020571

Jul 21, 2005

CAMPTOSAR

NDA NDA020571

Aug 1, 2006

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

May 14, 2010

CAMPTOSAR

NDA NDA020571

Jul 13, 2012

CAMPTOSAR

NDA NDA020571

Jan 17, 2013

CAMPTOSAR

NDA NDA020571

Jun 9, 2014

CAMPTOSAR

NDA NDA020571

Dec 19, 2014

CAMPTOSAR

NDA NDA020571

Oct 22, 2015

ONIVYDE

NDA NDA207793

Feb 22, 2019

CAMPTOSAR

NDA NDA020571

Jan 30, 2020

CAMPTOSAR

NDA NDA020571

Jan 27, 2022

CAMPTOSAR

NDA NDA020571

Jan 27, 2022

CAMPTOSAR

NDA NDA020571

Apr 4, 2024

CAMPTOSAR

NDA NDA020571

Sources

References

[1]
ClinicalTrials.gov — 642 trial records for Irinotecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Camptosar drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Irinotecan compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Irinotecan. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA020571). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Camptosar. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Topoisomerase I Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Patent Landscape[6]

Patent Cliff

Jan 6, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

8329213Jan 6, 2027

8147867Aug 29, 2028

9364473Jun 12, 2033

12364691Jun 12, 2033

11369597Jun 12, 2033

9 more patents

9339497Jun 12, 2033

9452162Jun 12, 2033

10980795Jun 12, 2033

9717724Jun 12, 2033

9492442Jun 12, 2033

11344552Aug 19, 2036

12059497Oct 15, 2036

10456360Oct 15, 2036

10993914Oct 15, 2036